XML 24 R14.htm IDEA: XBRL DOCUMENT
v3.25.3

Expenses | 12 Months Ended
--- | ---
Jun. 30, 2025
Disclosure [Abstract] |
Expenses | Note 7. Expenses Loss before income tax includes the following specific expenses:
|  | 2025 A$’000 |  |  | 2024 A$’000 |  |  | 2023 A$’000 |
Research and development expense |  |  |  |  |  |  |  |  |  |  |  |
EVT-801 program costs |  |  | 1,391 |  |  |  | 5,277 |  |  |  | 5,060 |
Cantrixil program costs |  |  | 2 |  |  |  | 1 |  |  |  | 5 |
Paxalisib program costs |  |  | 3,031 |  |  |  | 7,551 |  |  |  | 5,618 |
Scientific Advisory Board costs |  |  | — |  |  |  | — |  |  |  | 31 |
Employee benefits expense - salaries & wages and staff benefits |  |  | 1,761 |  |  |  | 2,161 |  |  |  | 2,250 |
- superannuation |  |  | 34 |  |  |  | 36 |  |  |  | 29 |
- share based payments |  |  | 172 |  |  |  | 485 |  |  |  | 702 |
Total research & development expense (excluding amortisation) |  |  | 6,391 |  |  |  | 15,511 |  |  |  | 13,695 |
Amortisation |  |  |  |  |  |  |  |  |  |  |  |
Paxalisib licensing agreement |  |  | 542 |  |  |  | 1,084 |  |  |  | 1,084 |
Evotech licensing agreement |  |  | 392 |  |  |  | 785 |  |  |  | 785 |
Total amortisation |  |  | 934 |  |  |  | 1,869 |  |  |  | 1,869 |
Total research & development expense |  |  | 7,325 |  |  |  | 17,380 |  |  |  | 15,564 |
Net foreign exchange loss |  |  |  |  |  |  |  |  |  |  |  |
Net foreign exchange loss/(gain) |  |  | 310 |  |  |  | (20 | ) |  |  | 46 |
Lease |  |  |  |  |  |  |  |  |  |  |  |
Expense relating to short term lease |  |  | 59 |  |  |  | 124 |  |  |  | 152 |
Superannuation expense |  |  |  |  |  |  |  |  |  |  |  |
Defined contribution superannuation expense |  |  | 54 |  |  |  | 88 |  |  |  | 131 |
Employee benefits expense G&A |  |  |  |  |  |  |  |  |  |  |  |
- salaries & wages and staff benefits |  |  | 1,062 |  |  |  | 486 |  |  |  | 1,467 |
- superannuation |  |  | 20 |  |  |  | 52 |  |  |  | 102 |
- share based payments |  |  | 481 |  |  |  | 48 |  |  |  | 457 |
Total employee benefits expense G&A |  |  | 1,563 |  |  |  | 586 |  |  |  | 2,026 |

X
- Definition The disclosure of expenses. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Note Expiry date 2027-01-01 -Name IAS -Number 1 -IssueDate 2025-01-01 -Paragraph 10 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfExpensesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | kzia_DisclosureAbstract
Namespace Prefix: | kzia_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration